Fig. 5.

. Effects of FGF1^ΔHBS-FGF21^C-tail on blood glucose levels and insulin sensitivity in db/db mice

(a) Changes in blood glucose levels of db/db mice following an acute intraperitoneal injection of FGF1^ΔHBS-FGF21^C-tail, FGF21^WT or FGF1^ΔHBS (0.5 mg/kg body weight) over the course of 24 h; db/db mice treated with buffer alone (PBS) and their littermates (db/m) served as controls. Data are presented as mean +/- SEM (n = 5). *p<0.05, **p<0.01, ***p<0.001 vs db/db; ^#p<0.05, ^##p<0.01, ^###p<0.001 vs FGF21^WT treatment, unpaired t-test. (b–d) Fed-state blood glucose levels (b), body weight (c) and food intake (d) of db/db mice over the course of 24 days of daily subcutaneous administration of FGF1^ΔHBS-FGF21^C-tail, FGF21^WT or FGF1^ΔHBS (0.5 mg/kg body weight). Data are presented as mean +/- SEM (n = 6). *p<0.05, ***p<0.001 vs db/db; ^###p<0.001 vs FGF21^WT treatment, unpaired t-test. (e) Serum insulin levels of db/db mice after a 24-day course of treatment with FGF1^ΔHBS-FGF21^C-tail, FGF21^WT or FGF1^ΔHBS administered as in (b). Data are presented as mean +/- SEM (n = 6). **p<0.01, ***p<0.001 vs db/db; ^##p<0.01 vs FGF21^WT treatment, unpaired t-test. (f,g) Glucose tolerance test in db/db mice performed 12 h after the final injection (on day 24) of sequential administration with FGF1^ΔHBS-FGF21^C-tail, FGF21^WT or FGF1^ΔHBS as detailed in (b). Changes in blood glucose levels (e) and integrated area under the curve (AUC) (f) are shown. Data are presented as mean +/- SEM (n = 6). *p<0.05, ***p<0.001 vs db/db; ^###p<0.001 vs FGF21^WT treatment, unpaired t-test.